DELAURO VISITS INNOVATIVE LOCAL BIOPHARMACEUTICAL COMPANY

Washington, DC — Congresswoman Rosa DeLauro (D-CT) today toured the facilities of Biomedisyn, a Woodbridge, Connecticut biopharmaceutical company focused on developing small molecule drugs to treat central nervous system disorders. There, she met with Frank Volvovitz, President of Biomedisyn, and Dr. Scott Woods, Professor of Psychiatry at Yale.

"It is always exhilarating to see ground-breaking biomedical research being conducted right here in our district," said Congresswoman DeLauro. "At Biomedisyn, researchers are working on everything from creating new treatments for the prevention and treatment of schizophrenia and neurological complications accompanying HIV/AIDS to protecting our troops from nerve agent attacks. It is great to see Connecticut scientists and researchers pursuing fundamental knowledge about how we grow, age, and become ill, and I am proud to see the federal government is supporting these efforts. In my role as Ranking Member on the Labor, Health and Human Services, and Education appropriations subcommittee, I will continue to fight to see that we are investing in biomedical research that advances the frontiers of knowledge, helps to cure disease, creates good jobs and grows the economy."

Founded in 1994, Biomedisyn employs a staff of seven, including four Ph.D. scientists. Its drug development pipeline, supported by federal grants, includes both clinical and preclinical candidates, which have shown benefits across a range of laboratory disease models including Alzheimer's disease, ALS, and HIV/AIDS. Biomedisyn has received two STTR (Small Business Technology Transfer) grants through the National Institutes of Health to pursue biomedical research. In addition, Biomedisyn has received money through the Defense Department to develop a new drug to prevent nerve agent injury.